Convergent Validity of New Disease Assessment Instruments in Systemic Lupus Erythematosus in Relation to Sledai-2K

被引：0
|
作者：
Collins, Christopher [1 ]
Chatham, W. Winn [2 ]
Busch, Howard [3 ]
Gaylis, Norman B. [4 ]
Hautamaki, Emily [5 ]
Narayanan, Siva [6 ]
机构：
[1] MedStar Washington Hosp Ctr, Washington, DC USA
[2] Univ Alabama Birmingham, Med Clin Immunol & Rheumatol, Birmingham, AL USA
[3] Sci & Res Inst, Jupiter, FL USA
[4] Arthrit & Rheumat Dis Specialties, Aventura, FL USA
[5] Ipsos Healthcare, Washington, DC USA
[6] Ipsos Healthcare, Global Evidence Value & Access, Washington, DC USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
771
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Development and Initial Validation of a Novel Lupus Disease Activity Index to Account for Glucocorticoids: SLEDAI-2K Glucocorticoids Index (SGI)
    Touma, Zahi
    Gladman, Dafna
    Su, Jiandong
    Urowitz, Murray
    [J]. JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 902 - 903
  • [32] The relationship between systemic lupus erythematosus disease activity index (SLEDAI) and cardiac affection
    Ghany, M. Abdel
    Nader, N.
    Youssef, A.
    Kishk, Y.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 101 - 101
  • [33] A RELIABILITY STUDY OF SLEDAI - A DISEASE-ACTIVITY INDEX FOR SYSTEMIC LUPUS-ERYTHEMATOSUS
    HAWKER, G
    GABRIEL, S
    BOMBARDIER, C
    GOLDSMITH, C
    CARON, D
    GLADMAN, D
    [J]. JOURNAL OF RHEUMATOLOGY, 1993, 20 (04) : 657 - 660
  • [34] SLEDAI-2K Responder Index-50 Is Effective in Demonstrating Partial Response in a Phase 2, Randomized Placebo-Controlled Study of Ustekinumab in Patients with Active Systemic Lupus Erythematosus
    Touma, Zahi
    Urowitz, Murray
    Gladman, Dafna D.
    Wagner, Carrie
    Zhou, Bei
    Gordon, Robert
    Hsu, Benjamin
    Chevrier, Marc
    Rose, Shawn
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [35] Measures of Adult Systemic Lupus Erythematosus Updated Version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)
    Romero-Diaz, Juanita
    Isenberg, David
    Ramsey-Goldman, Rosalind
    [J]. ARTHRITIS CARE & RESEARCH, 2011, 63 : S37 - S46
  • [36] SLE Disease Activity Index Glucocorticosteroid Index (SLEDAI-2KG) Identifies More Responders Than Sledai-2K
    Touma, Zahi
    Gladman, Dafna D.
    Su, Jiandong
    Anderson, Nicole
    Urowitz, Murray
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [37] CORRELATION BETWEEN THE EUROPEAN CONSENSUS LUPUS ACTIVITY MEASUREMENT (ECLAM) AND THE MODIFIED SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX 2000 (M-SLEDAI 2K) IN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS (JS']JSLE)
    Sato, J. O.
    Corrente, J. E.
    Magalhaes, C. S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 582 - 582
  • [38] Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus
    Mertz, Philippe
    Piga, Matteo
    Chessa, Elisabetta
    Amoura, Zahir
    Voll, Reinhard E.
    Schwarting, Andreas
    Maurier, Francois
    Blaison, Gilles
    Bonnotte, Bernard
    Poindron, Vincent
    Fiehn, Christoph
    Lorenz, Hanns-Martin
    Korganow, Anne-Sophie
    Sibilia, Jean
    Martin, Thierry
    Arnaud, Laurent
    [J]. RMD OPEN, 2022, 8 (02):
  • [39] Can the adjusted mean SLEDAI-2K predict organ damage and coronary artery disease?
    Matthew H Liang
    [J]. Nature Clinical Practice Rheumatology, 2006, 2 (1): : 10 - 11
  • [40] Validity of the Disease Repercussion Profile in patients with systemic lupus erythematosus
    Sharpe, L
    Denton, F
    Schrieber, L
    [J]. LUPUS, 2004, 13 (06) : 428 - 435
12345